logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Head and neck cancer: pembrolizumab+radiotherapy active, well-tolerated

Phase 2 study of cisplatin-ineligible patients reports good PFS.